Chris Bitterman - Cumberland Pharmaceuticals Vice Marketing
| CPIX Stock | USD 1.06 0.02 1.85% |
Executive
Chris Bitterman is Vice Marketing of Cumberland Pharmaceuticals
| Age | 59 |
| Address | 1600 West End Avenue, Nashville, TN, United States, 37203 |
| Phone | 615 255 0068 |
| Web | https://www.cumberlandpharma.com |
Cumberland Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0564) % which means that it has lost $0.0564 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3607) %, meaning that it created substantial loss on money invested by shareholders. Cumberland Pharmaceuticals' management efficiency ratios could be used to measure how well Cumberland Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.1 in 2024. Return On Capital Employed is likely to rise to -0.11 in 2024. At this time, Cumberland Pharmaceuticals' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 60.5 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 27.5 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Anuj MD | Assembly Biosciences | 46 | |
| Meredith MBA | Soleno Therapeutics | 52 | |
| Dr MBA | Soleno Therapeutics | N/A | |
| Alan MD | Crinetics Pharmaceuticals | 61 | |
| MD FACC | Capricor Therapeutics | 68 | |
| MBA MBA | Bio Path Holdings | N/A | |
| Chau MBA | CytomX Therapeutics | N/A | |
| Michael MD | Soleno Therapeutics | 50 | |
| Danielle OlanderMoghadassian | CytomX Therapeutics | N/A | |
| Tariq Ahmed | Achilles Therapeutics PLC | N/A | |
| PharmD MBA | Soleno Therapeutics | N/A | |
| ScD MD | Moleculin Biotech | 72 | |
| Edward Samuel | Achilles Therapeutics PLC | N/A | |
| Gayathri Diwakar | Crinetics Pharmaceuticals | N/A | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| Garlan Adams | Crinetics Pharmaceuticals | N/A | |
| MBA Ashizawa | Bio Path Holdings | N/A | |
| Kristen MS | Soleno Therapeutics | 55 | |
| Dana MD | Crinetics Pharmaceuticals | 68 | |
| Richard Colonno | Assembly Biosciences | 74 | |
| Anthony Price | Bio Path Holdings | N/A | |
Management Performance
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.0564 |
Cumberland Pharmaceuticals Leadership Team
Elected by the shareholders, the Cumberland Pharmaceuticals' board of directors comprises two types of representatives: Cumberland Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cumberland. The board's role is to monitor Cumberland Pharmaceuticals' management team and ensure that shareholders' interests are well served. Cumberland Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cumberland Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Hamm, Chief Officer | ||
| John CMA, VP CFO | ||
| Todd Anthony, Vice Development | ||
| James Herman, Chief Compliance Officer and VP of National Accounts | ||
| Adam Mostafa, Managing Director | ||
| Erin Gull, Senior Associate | ||
| Jean Marstiller, Senior Secretary | ||
| Chris Bitterman, Vice Marketing | ||
| A MBA, Chairman, Founder | ||
| Cindy Patton, Director Marketing |
Cumberland Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cumberland Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.0564 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 18.9 M | ||||
| Shares Outstanding | 14.04 M | ||||
| Shares Owned By Insiders | 44.72 % | ||||
| Shares Owned By Institutions | 14.68 % | ||||
| Number Of Shares Shorted | 76.74 K | ||||
| Price To Earning | (16.05) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cumberland Stock Analysis
When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.